5712 Results

People

  1. Drilon
    Drilon
  2. Perales
    Perales
  3. Giralt
    Giralt
  4. Motzer
    Motzer
  5. Ladanyi
    Ladanyi
  6. Morrow
    Morrow
  7. Rimner
    Rimner
  8. O'Reilly
    O'Reilly
  9. Horwitz
    Horwitz
  10. Jones
    Jones

Groups

  1. Department of Medicine (2534)
  2. Solid Tumor Oncology Division (1517)
  3. Sloan Kettering Institute Postdocs (1176)
  4. GSK Faculty (1088)
  5. Surgery (954)
  6. Survivorship Research (922)
  7. Hematologic Malignancies, Division of (875)
  8. Center for Hematologic Malignancies (802)
  9. Population Sciences Research Program (786)
  10. Department of Pathology and Laboratory Medicine (677)
  1. "2021"
Formats
  1. Journal Article (2507)
  2. Meeting Abstract (1731)
  3. Review (604)
  4. Editorial (358)
  5. Book Section (123)
  6. Correspondence (107)
  7. Guidelines (103)
  8. Research Letter (91)
  9. Miscellaneous (52)
  10. Conference Paper (34)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2534)
  2. Solid Tumor Oncology Division (1517)
  3. Sloan Kettering Institute Postdocs (1176)
  4. GSK Faculty (1088)
  5. Surgery (954)
  6. Survivorship Research (922)

More Groups

People
  1. Alexander Drilon (76)
  2. Miguel-Angel Perales (68)
  3. Sergio Giralt (66)
  4. Robert Motzer (65)
  5. Marc Ladanyi (62)
  6. Monica Morrow (57)

More People

Years
  1. 2021 (5712)
Publications
  1. Journal of Clinical Oncology (471)
  2. Blood (252)
  3. Annals of Oncology (148)
  4. Cancer Research (145)
  5. International Journal of Radiation Oncology, Biology, Physics (145)
  6. Journal of Thoracic Oncology (101)

More Publications

Publishers
  1. Elsevier Inc. (723)
  2. American Society of Clinical Oncology (522)
  3. Springer (381)
  4. Oxford University Press (360)
  5. Nature Publishing Group (344)
  6. American Association for Cancer Research (297)

More Publishers

Results (5712)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation
    Meeting Abstract

    Riely, G. J.; Ou, S. H. I.; Rybkin, I.; Spira, A.; Papadopoulos, K.; Sabari, J. K.; Johnson, M.; Heist, R. S.; Bazhenova, L.; Barve, M.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with METexon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION cohort A
    Meeting Abstract

    Scherz, A.; Sakai, H.; Le, X.; Felip, E.; Veillon, R.; Garassino, M. C.; Raskin, J.; Viteri, S.; Mazieres, J.; Cortot, A.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Long-term efficacy and genomic characteristics of patients with TRK fusion lung cancer treated with larotrectinib
    Meeting Abstract

    Moreno Garcia, V.; Lin, J.; Patel, J.; Lassen, U.; Solomon, B.; Rosen, L.; Leyvraz, S.; Tan, D. S. W.; Reeves, J. A.; Beckmann, G.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • A phase 2 trial of MRTX849 in combination with pembrolizumab in patients with advanced non-small cell lung cancer with KRAS G12C mutation
    Meeting Abstract

    Spira, A.; Riely, G.; Lawler, W.; Shum, M.; Socinski, M.; Yanagihara, R.; Roshan, S.; Kheoh, T.; Christensen, J.; Chao, R.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
    Meeting Abstract

    Paz-Ares, L.; Owonikoko, T. K.; Johnson, M.; Govindan, R.; Izumi, H.; Lai, V.; Borghaei, H.; Boyer, M.; Boosman, R. J.; Hummel, H. D.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy
    Meeting Abstract

    Spigel, D. R.; Peters, S.; Ahn, M. J.; Tsuboi, M.; Chaft, J.; Harpole, D.; Barlesi, F.; Abbosh, C.; Mann, H.; May, R.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Phase 2 study of zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors
    Meeting Abstract

    Schram, A.; Macarulla, T.; O'Reilly, E.; Rodon, J.; Wolpin, B.; Ou, S.; Kim, D.; Yang, J. C.; Lam, J.; De Langen, A.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Activity of tepotinib in brain metastases (BM): Preclinical and clinical data in MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Mazieres, J.; Veillon, R.; Felip, E.; Le, X.; Garassino, M. C.; Stanton, T.; Morise, M.; Lee, J.; Matsumoto, S.; De Marinis, F.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • A phase 2 study of erdafitinib in patients with advanced solid tumors and fibroblast growth factor receptor gene alterations
    Meeting Abstract

    Pant, S.; Tabernero, J.; Massard, C.; Hyman, D. M.; Witt, O.; Doi, T.; Qin, S.; Lu-Emerson, C.; Hargrave, D.; Garcia-Corbacho, J.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • 3D analysis of spread through air spaces in squamous cell carcinoma and carcinoid tumor using whole block imaging by micro CT
    Meeting Abstract

    Inoue, T.; Teplov, A.; Rekhtman, N.; Chida, M.; Travis, W.; Yagi, Y.
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save